Advances in recombinant DNA technology, protein and metabolic engineering and in silico investigation have led to the use of cytotoxic products of microorganisms for anti-cancer drugs development based on targeting cell surface antigens of cancerous cells, which are known as immunotoxins. Therefore, understanding the structural and functional characteristics of these types of the antigens, while leading to present a new way for cancer diagnosis, provide us targets for immunotoxins designing. Considering, reported cancerous cell surface specific antigens of various tissues were gathered, and then corresponding nucleotide and protein sequences as well as 3D structures of them were derived from related databanks. Subsequently, several in silico programs were used for sequence, interaction, as well as expression characterization on normal and cancerous tissues. The results of this analysis lead to the disclosure cell surface specific antigens including PSMA, PSA, EPCAM, GPA33, EPHA3, IGFIR, AFP, CEA CAM 7, CEACAM5, CEA CAM3, CA15-3, NSE, HCG, MSLN, and MAGE4 with different expression on normal and cancerous tissues, and 27 key matching ligands. Among these antigens, MAGE4 showed high expression on the cell surface of 20 different of cancer tissues. Meanwhile, nucleotide and protein sequence analysis of the antigens and corresponding ligands lead to provide a series of therapeutic targets for immunotoxins designing as well as for cancer diagnosis, which ought to be more tested.
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The etiology of this devastating disease includes both exogenous (tobacco, infectious organisms, chemicals, radiation) and endogenous factors (inherited mutations, epigenetic changes, hormones) (7, 8) . However, cancer treatments do not have potent medicine as the currently available drugs and surgery approaches are causing side effects in some instances such as bleeding, hair loss, diarrhea, development of multidrug resistance, and immunosuppression (9) (10) (11) . Considering new drug development has shifted from cytotoxic agents to molecularly targeted therapy, supplementing or a combined of conventional and modern anticancer therapies to achieving treatment approaches which should act exclusively against tumor cells; without side effects on the human body (1, 12) . In this regard, a growing number of molecularly targeted agents such as monoclonal antibodies and immunotoxins approved for the treatment of malignancies (13) (14) (15) . In this context, immunotoxins pipeline consists of a Food and Drug Administration (FDA) approved as ONTAK, as well as several in different phases of the clinical pipeline and a large number of them in the preclinical pipeline (16) (17) (18) .Immunotoxins that are smart fusion proteins of toxic and ligands components, targeting cancer cells via cell-surface specific antigens as target (19) . The clinical development of immunotoxins suffering by a variety of problems such as poor antigen specificity, low cytotoxicity, and immunogenicity which some of them including improvement of tumor targeting considered in this study based on in silico investigation. Moreover, in silico expression assays were carried out in at least triplicate, and the generated data were expressed as mean _ standard deviation. One-way analysis of variance (ANOVA) was used to analyze the antigen expression on different tissues. ANOVA was done by a Tukey post hoc test. Statistical significance was considered at P < 0.05. All statistical analyses were carried out with SPSS 16.0 (SPSS Inc., Chicago, IL, USA).
RESULTS
Antigen profiling led to disclosure a series of specific antigens with various expressions on the cell surface of malignant cells (table 1) . As showed in this table, these antigens encoded from different genes with various characteristic. On the other hand, this data reveal that some of the cancerous cells could be expressed several antigens at different levels.
Moreover, in silico expression assay of the selected antigens showed different data from literature. So that the most of them could be expressed at least at different level from very low up to very high on the cell surface of 20 malignant tissues which are including Breast, Carcinoid, Cervical, Colorectal, Endometrial, Melanoma, Ovarian, Pancreatic, Prostate, Renal, Skin, Stomach, Testis, Glioma, Thyroid, Head and neck, Urothelial, Liver, Lung, Lymphoma. Nonetheless, some of these antigens showed expression on the surface of the normal cells. However, assessment the validity of detected ligands based on scoring and binding affinity ( Figure  3 ), led to the selection 8 proteins among 150 ligands which are including FLNA, SERPINA1, LHB, PSCA, ZBTB17, CLDN7, HLA-A, SRC with suitable in structure and binding affinity to the their antigens. As showed in the figure 4 among these ligands, ZBTB17 showed the highest binding affinity to corresponding antigen.
Conclusion:
Analysis of the nucleotide sequences of the selected antigens led to pr oviding significant data for biomarker investigation (data not shown). Taken together, the results of this research provide several cell surface specific antigens of malignancies with corresponding ligands that could be application in cancer target therapy. Meanwhile a series of the sequences were gathered which could be provide material for biomarker investigation in cancer diagnosis and cancer prognosis. Interaction between MAGE4 and ZBTB17 in 3D structure, hydrogen bonds and corresponding involved amino acid in interaction between ligand and antigen showed with discontinued yellow lines
